Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07262060 · ClinicalTrials.gov registry record · Phase 2
Improving Preterm Kidney Outcomes With Caffeine
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT07262060 is a Phase 2 study that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 114 participants.
The verdict
NCT07262060, a Phase 2 study, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilogram daily maintenance). The investigators hypothesize that additional caffeine will improve kidney oxygen levels, while not causing any brain injury, and may reduce rates of acute kidney injury compared to placebo. This study will take place in preterm babies born less than 30 weeks gestational age, with the intervention occurring between greater than 48 hours of age until DOL 14 and outcomes tracked until neonatal intensive care unit (NICU) discharge.
Interventions
- DRUG Placebo
- DRUG Caffeine citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07262060
The ClinicalTrials.gov registry entry for NCT07262060 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07262060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07262060 about?
NCT07262060 is a clinical study titled "Improving Preterm Kidney Outcomes With Caffeine". This study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilogram daily maintenanc...
What is the current status of trial NCT07262060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2026-05-28. Estimated completion is 2030-09.
What interventions are being tested in trial NCT07262060?
The interventions under investigation include: Placebo (DRUG), Caffeine citrate (DRUG).
Who is sponsoring clinical trial NCT07262060?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.